Home・Elenco Azioni・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Aperta

SettoreSettore sanitario

26.8 0.19

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

26.01

Massimo

27.12

Metriche Chiave
By Trading Economics
Entrata	93M -92M
Vendite	78M 214M
EPS	-0.9
Margine di Profitto	-42.991
Dipendenti	1,371
EBITDA	94M -61M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+88.91% upside

Dividendi
By Acuity
Utili prossimi	3 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	178M 2.6B
Apertura precedente	26.61
Chiusura precedente	26.8

Notizie sul Sentiment di mercato

By Acuity

50%

135 / 340 Classifica in Healthcare

Ultragenyx Pharmaceutical Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 ago 2026, 19:36 UTC

News

Ultragenyx Pharmaceutical reached a settlement with Esjay Pharma over DOJOLVI patent litigation, allowing a generic version to launch in 2023. Shares are higher today.

10 ago 2026, 19:16 UTC

News

HC Wainwright reiterated its Buy rating on Ultragenyx Pharmaceutical, maintaining a $50 price target, contributing to shares trading higher during the session.

7 ago 2026, 20:03 UTC

News

Ultragenyx Pharmaceutical reported a loss of -$0.90 per share, beating estimates. Revenue of $214 million also exceeded expectations, but shares are trading roughly flat.

6 ago 2026, 23:21 UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, showing unusual strength despite remaining below their 20-day moving average.

5 ago 2026, 19:52 UTC

News

Ultragenyx shares are lower after Wells Fargo cut its price target to $45. The company reported an EPS loss of $0.90, exceeding expectations.

4 ago 2026, 23:02 UTC

News

Ultragenyx Pharmaceutical reported second-quarter revenue of $214 million and narrowed its net loss to $92 million, with shares trading higher in after-market hours.

3 ago 2026, 22:51 UTC

Ultragenyx Pharmaceutical shares are trading roughly flat after-market. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

31 lug 2026, 19:52 UTC

Correlated Moves

Ultragenyx Pharmaceutical is lower today amid a decline in the Biotechnology sub-sector, with shares near the lower end of their one-month range.

30 lug 2026, 19:58 UTC

Correlated Moves

Ultragenyx rises, supported by SPDR S&P Biotech ETF gains.

29 lug 2026, 18:43 UTC

Ultragenyx Pharmaceutical is lower today, continuing a decline amid broader market pressures from rising crude oil prices and geopolitical tensions.

28 lug 2026, 19:03 UTC

Ultragenyx Pharmaceutical Inc shares are trading lower, reflecting a challenging performance backdrop amid strength in U.S. mega-cap stocks. No specific news was identified.

27 lug 2026, 19:07 UTC

Ultragenyx Pharmaceutical Inc shares are higher as crude oil prices decline, easing geopolitical concerns. No specific company news was identified for the move.

24 lug 2026, 19:51 UTC

Ultragenyx Pharmaceutical Inc shares are declining, continuing a trend of lower daily closes. Broader market volatility and new tariffs may be contributing factors.

22 lug 2026, 19:36 UTC

Ultragenyx Pharmaceutical shares are declining amid rising crude oil prices due to U.S.-Iran tensions. The stock remains below its 20-day moving average.

21 lug 2026, 19:22 UTC

Correlated Moves

Rising amid broader market gains and SPDR S&P Biotech support.

20 lug 2026, 19:17 UTC

Correlated Moves

Ultragenyx Pharmaceutical is declining amid a broader downturn in the Biotechnology sector, continuing a trend of seven consecutive lower sessions.

Confronto tra pari

Modifica del prezzo

Ultragenyx Pharmaceutical Inc Previsione

Obiettivo di Prezzo

By TipRanks

88.91% in crescita

Previsioni per 12 mesi

Media 50.93 USD 88.91%

Alto 96 USD

Basso 27 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ultragenyx Pharmaceutical Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 15 che hanno fornito valutazioni azionarie a Ultragenyx Pharmaceutical Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

135 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.